Videos

Phillip S. Low, PhD, spoke about what the future holds for treatments like 177Lu-PSMA-617 being developed for patients with prostate cancer.

Panelists consider key risk factors for chronic GVHD, including the degree of donor transplant matching, patient age, intensity of conditioning, use of ablative doses of total-body radiation, and presence of acute GVHD.

Pashna N. Munshi, MD, and Yi-Bin Chen, MD, examine key differences in the pathologic features of acute and chronic GVHD.

Ursula A. Matulonis, MD, discusses key data with mirvetuximab soravtansine for patients with folate receptor α–high platinum-resistant ovarian cancer that read out of the phase 3 SORAYA trial.

Matthew Krebs, MB, PhD spoke about the reasoning for the phase 1 PALOMA trial in patients with solid tumors who received a subcutaneous formulation of amivantamab.

Shared insight on the selection of specific androgen receptor inhibitors for patients with nonmetastatic castration-resistant prostate cancer.

Centering the discussion around a patient with nonmetastatic castration-resistant prostate cancer, experts share insight on optimal work-up and testing.

Stéphane Champiat, MD, PhD, spoke about the results of the AURELIO-03 trial with SOT101 and pembrolizumab for patients with advanced solid tumors.

Shared insight on the adverse event profile of immunotherapy combination regimens in renal cell carcinoma, including advice on when it is appropriate to discontinue therapy.

Expert perspectives on the triplet combination of ixazomib, pomalidomide, and dexamethasone in multiple myeloma presented at the 2021 ASH [American Society of Hematology] Annual Meeting.

Expert perspectives on the clinical scenario of a patient with intermediate-risk renal cell carcinoma, who is managed with the immunotherapy combination of ipilimumab and nivolumab.

Continuing their discussion on the management of multiple myeloma, experts Paul Richardson, MD, and Cristina Gasparetto, MD, consider the value of minimal residual disease as a marker.

Frederick Lock, MD, spoke about the approval of axicabtagene ciloleucel and how it’s beneficial for patients with large B-cell lymphoma who were treated with frontline chemoimmunotherapy.

A prostate cancer expert discusses promising and emerging treatments for prostate cancer.

Dr Choudhury shares recent updates from 2021 meetings including ASCO GU, AUA, and ESMO.

Lori Wirth, MD, defines radioiodine-refractory differentiated thyroid cancer and discusses frontline treatment options for patients with the disease.

Hannah Choe, MD, guides the panel in a conversation on the protective effects of acute and chronic GVHD including the potential impact on leukemic relapse.

A panel of key opinion leaders in stem cell transplant and cellular immunotherapy reviews the hallmark signs and symptoms of acute GVHD.

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about how the conference catered to the multidisciplinary audience, and what he learned from that.

Anjali Y. Hari, MD, speaks to the rationale for examining hyperthermic intraperitoneal chemotherapy in a population of frail and non-frail patients with ovarian cancer.

Expert perspectives on the use of LHRH agonists versus antagonists in the management of prostate cancer.

A comprehensive overview on androgen-deprivation therapy in prostate cancer and the various therapeutic agents it consists of.

In a discussion with CancerNetwork®, Ursula A. Matulonis, MD, describes the potential of mirvetuximab soravtansine (IMGN853) as a treatment for patients with folate receptor α (FRα)–high platinum-resistant ovarian cancer.

Ira Winer, MD, PhD, FACOG, spoke about patients with pretreated platinum-resistant ovarian cancer treated with nemvaleukin alfa plus pembrolizumab in the phase 1/2 ARTISTRY-1 trial.

Anjali Hari, MD, discusses survival and safety outcomes with hyperthermic intraperitoneal chemotherapy in frail and non-frail patients with ovarian cancer.

A review of the available first-line treatment options for transplant-ineligible multiple myeloma, as well as the design and findings of the MAIA study.

Experts explain how to determine treatment duration and a successful response to induction therapy for transplant-eligible multiple myeloma.

A look at the factors considered in choosing an appropriate combination treatment for advanced renal cell carcinoma.

Drs Rana McKay and Tom Powles debate the merits of different first-line combination treatment regimens for renal cell carcinoma.

Prostate cancer experts share exciting changes to the prostate cancer treatment landscape and how we are now better equipped to take care of patients with prostate cancer.